REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)

Le résumé fourni par la source

Introduction: In a study of patients (pts) with PAH (REPAIR), macitentan improved RV stroke volume (RVSV) and measures of RV function at Week 26. Aims and objectives: To assess if effects of macitentan at Week 26 were maintained at Week 52. Methods: REPAIR (NCT02310672) was a 52-week, multicentre, open-label, single-arm phase 4 study. Macitentan 10mg was initiated in treatment-naïve PAH pts, in pts receiving stable background phosphodiesterase type-5 inhibitor (PDE5i) at baseline (BL), or in initial combination with PDE5i. RV MRI variables, 6-minute walk distance (6MWD) and WHO functional class (FC) were assessed at Weeks 26 and 52. Results: Analyses included 71 pts (80% female; BL: median age 45 years, median 6MWD 395 [Q1, Q3: 323, 483] m, 98.6% FC II/III. At Weeks 26 and 52, mean (95% CL) change from BL in 6MWD was 36 (19, 52) and 38 (19, 57) m; FC improved in 40/70 (56%) and 34/65 (48%) pts; no pts worsened. The table shows RV parameter changes at Weeks 26 and 52. Conclusions: Improvements in RV mass, volume and function observed with macitentan at Week 26 were maintained at Week 52.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.